Deutsche Bank analyst David Hoang upgraded Acadia Pharmaceuticals (ACAD) to Buy from Hold with a $35 price target The firm sees an attractive setup for the company’s Prader-Willi syndrome opportunity after a district court ruled in favor of Acadia regarding its formulation patent for Nuplazid.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals upgraded to Buy from Hold at Deutsche Bank
- Acadia Pharmaceuticals price target raised to $24 from $20 at Morgan Stanley
- Biotech Alert: Searches spiking for these stocks today
- Acadia Pharmaceuticals price target raised to $28 from $24 at BMO Capital
- Acadia Pharmaceuticals price target raised to $23 from $20 at Mizuho